Brokerages Expect Transenterix Inc (TRXC) Will Announce Quarterly Sales of $1.82 Million
Analysts predict that Transenterix Inc (NYSE:TRXC) will announce $1.82 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Transenterix’s earnings, with the lowest sales estimate coming in at $1.74 million and the highest estimate coming in at $1.90 million. Transenterix reported sales of $1.47 million during the same quarter last year, which would suggest a positive year over year growth rate of 23.8%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Transenterix will report full year sales of $1.82 million for the current financial year, with estimates ranging from $8.65 million to $9.20 million. For the next fiscal year, analysts expect that the firm will post sales of $33.33 million per share, with estimates ranging from $31.50 million to $35.16 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Transenterix.
WARNING: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/09/brokerages-expect-transenterix-inc-trxc-will-announce-quarterly-sales-of-1-82-million.html.
Transenterix (NYSE:TRXC) traded up 12.00% during mid-day trading on Friday, hitting $1.12. The stock had a trading volume of 1,697,327 shares. The firm’s market cap is $166.36 million. Transenterix has a 12-month low of $0.45 and a 12-month high of $2.33. The stock has a 50-day moving average price of $0.77 and a 200 day moving average price of $0.84.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.